Literature DB >> 28792386

After Charlie Gard: ethically ensuring access to innovative treatment.

Dominic Wilkinson1, Julian Savulescu2.   

Abstract

Mesh:

Year:  2017        PMID: 28792386     DOI: 10.1016/S0140-6736(17)32125-6

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

1.  What is a reasonable framework for new non-validated treatments?

Authors:  Gert Helgesson
Journal:  Theor Med Bioeth       Date:  2021-02-14

Review 2.  Recent developments in genetic/genomic medicine.

Authors:  Rachel H Horton; Anneke M Lucassen
Journal:  Clin Sci (Lond)       Date:  2019-03-05       Impact factor: 6.124

3.  Combining the best interest standard with shared decision-making in paediatrics-introducing the shared optimum approach based on a qualitative study.

Authors:  Jürg Caspar Streuli; James Anderson; Sierra Alef-Defoe; Eva Bergsträsser; Jovana Jucker; Stephanie Meyer; Sophia Chaksad-Weiland; Effy Vayena
Journal:  Eur J Pediatr       Date:  2020-08-18       Impact factor: 3.183

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.